» Articles » PMID: 15541124

Treatment of Stress Urinary Incontinence Using a Copolymer System: Impact on Quality of Life

Overview
Journal BJU Int
Specialty Urology
Date 2004 Nov 16
PMID 15541124
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the effect on quality of life (QoL) of a novel system for treatment of stress urinary incontinence (SUI).

Patients And Methods: In an open, prospective, multicentre study, 42 women not previously treated by invasive therapy and with urodynamically verified SUI received 4 x 1.0 mL or 4 x 0.7 mL of non-animal stabilized hyaluronic acid/dextranomer copolymer injected transurethrally into the urethra via the Implacer device (Zuidex system, Q-Med AB, Uppsala, Sweden). QoL was assessed using the King's Health Questionnaire. The patients' perception of treatment benefit and the number of incontinence episodes/24 h were also investigated.

Results: There were significant improvements over baseline in seven of 10 domains of the King's Health Questionnaire at 3 months, and these improvements were sustained at 1 year. For the change from baseline to 1 year, eight of 10 domains showed a significant positive correlation with the number of incontinence episodes/24 h. In terms of treatment benefit, most of the women perceived an improvement at 1, 3, 6 and 12 months. Of the 18 women requiring re-treatment, most perceived an improvement at 3, 6 and 12 months.

Conclusion: Treatment with the Zuidex system produced significant improvements over a year in both subjective QoL and objective incontinence measures, with a significant positive correlation between them.

Citing Articles

Animal models, treatment options, and biomaterials for female stress urinary incontinence.

Tan X, Li G, Li C, Kong C, Li H, Wu S Front Bioeng Biotechnol. 2024; 12:1414323.

PMID: 39267906 PMC: 11390547. DOI: 10.3389/fbioe.2024.1414323.


Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI).

Lone F, Sultan A, Thakar R Int Urogynecol J. 2010; 21(11):1359-64.

PMID: 20571764 DOI: 10.1007/s00192-010-1211-4.


Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?.

Starkman J, Scarpero H, Dmochowski R Curr Urol Rep. 2006; 7(5):405-13.

PMID: 16959180 DOI: 10.1007/s11934-006-0012-2.


Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy.

Chapple C, Brubaker L, Haab F, Van Kerrebroeck P, Robinson D Int Urogynecol J Pelvic Floor Dysfunct. 2006; 18(2):199-205.

PMID: 16847584 DOI: 10.1007/s00192-006-0148-0.